Search research articles
Contact Us
Filters
Showing results (351-360 of 366) with videos related to
Page
of 37
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 30, 2013
Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy
George D Demetri, Sant P Chawla, Isabelle Ray-Coquard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 16, 2017
A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors
Andrea E Wahner Hendrickson, Michael E Menefee, Lynn C Hartmann, et al.
Gynecologic Oncology
|
October 13, 2021
Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer
G E Konecny, A E Wahner Hendrickson, T M Davidson, et al.
The Lancet. Oncology
|
April 17, 2016
Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial
Jeffrey H Lipton, Charles Chuah, Agnès Guerci-Bresler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 6, 2017
Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial
Dong-Wan Kim, Marcello Tiseo, Myung-Ju Ahn, et al.
Cancers
|
April 9, 2020
Disruption of Glycogen Utilization Markedly Improves the Efficacy of Carboplatin against Preclinical Models of Clear Cell Ovarian Carcinoma
Tashbib Khan, Yaowu He, Thomas Kryza, et al.
Blood
|
March 24, 2018
Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial
Jorge E Cortes, Dong-Wook Kim, Javier Pinilla-Ibarz, et al.
The New England Journal of Medicine
|
November 5, 2013
A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias
J E Cortes, D-W Kim, J Pinilla-Ibarz, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]
|
December 3, 2019
Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer
Angela L McCleary-Wheeler, Ryan M Carr, Shanique R Palmer, et al.
NAR Cancer
|
July 28, 2021
Characterization of a <i>RAD51C</i>-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance
Rachel M Hurley, Cordelia D McGehee, Ksenija Nesic, et al.
Page
of 37
Search research articles
Search
Showing results (351-360 of 366) with videos related to
Sort By:
Page
of 37
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 30, 2013
Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy
George D Demetri, Sant P Chawla, Isabelle Ray-Coquard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 16, 2017
A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors
Andrea E Wahner Hendrickson, Michael E Menefee, Lynn C Hartmann, et al.
Gynecologic Oncology
|
October 13, 2021
Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer
G E Konecny, A E Wahner Hendrickson, T M Davidson, et al.
The Lancet. Oncology
|
April 17, 2016
Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial
Jeffrey H Lipton, Charles Chuah, Agnès Guerci-Bresler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 6, 2017
Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial
Dong-Wan Kim, Marcello Tiseo, Myung-Ju Ahn, et al.
Cancers
|
April 9, 2020
Disruption of Glycogen Utilization Markedly Improves the Efficacy of Carboplatin against Preclinical Models of Clear Cell Ovarian Carcinoma
Tashbib Khan, Yaowu He, Thomas Kryza, et al.
Blood
|
March 24, 2018
Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial
Jorge E Cortes, Dong-Wook Kim, Javier Pinilla-Ibarz, et al.
The New England Journal of Medicine
|
November 5, 2013
A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias
J E Cortes, D-W Kim, J Pinilla-Ibarz, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]
|
December 3, 2019
Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer
Angela L McCleary-Wheeler, Ryan M Carr, Shanique R Palmer, et al.
NAR Cancer
|
July 28, 2021
Characterization of a <i>RAD51C</i>-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance
Rachel M Hurley, Cordelia D McGehee, Ksenija Nesic, et al.
Page
of 37